Antihyperglycemic and antidiabetic effects of Ethyl (S)-2-(1-cyclohexylsulfamide carbamoyloxy) propanoate in streptozotocin-induced diabetic Wistar rats
Loading...
Date
2016-03
Journal Title
Journal ISSN
Volume Title
Publisher
Université de M'sila
Abstract
In this study, we examined the antihyperglycemic and antidiabetic effects of a novel synthesized molecule,
the Ethyl (S)-2-(1-cyclohexylsulfamide carbamoyloxy) propanoate (ESP1b), in streptozotocin
(STZ)-induced diabetic Wistar rats. Experimental diabetes mellitus was produced by a single intraperitoneal
injection of STZ (55 mg/kg b.w.). Seven day post-injection, animals have received ESP1b
orally at the doses of 5, 10 and 20 mg/kg b.w. daily for 28 days. This resulted in a clear decline, in a dose
dependent manner, of blood glucose levels during the oral glucose tolerance test (OGTT) and the four
weeks of treatment period. ESP1b at 20 mg/kg b.w. has alleviated body weight loss, improved plasma
insulin concentration and at the same time markedly decreased the values of glycosylated hemoglobin,
lipoproteins and atherogenic ratios. Additionally, ESP1b notably restored renal as well as hepatic functions
tests. Histopathological examinations of pancreatic tissue also confirmed the previous biochemical
findings. Considering the obtained results, it may be concluded that ESP1b possess a potent antihyperglycemic
activity in STZ-diabetic rats possibly related to an insulin-secretagogue effect, which may
be responsible for the moderate decrease in blood glucose concentration observed in normal rats administrated
with this tested compound.
Description
Keywords
Experimental diabetes Insulin-secretagogue Streptozotocin Sulfonamide